Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Participants needed: 312
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Rapport Therapeutics Inc.Updated: Jun 25, 2026Locations: 3
Eligibility criteria

Age 18 - 75 [+5]

Known hypersensitivity or prior exposure to RAP-219. [+8]

Read more
Status: Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.

Participants needed: 250
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Rapport Therapeutics Inc.Updated: Jun 22, 2026Locations: 22
Eligibility criteria

Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (... [+1]

History of any of the following diagnoses: a. schizophrenia; schizoaffective dis... [+1]

Read more
Status: Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Participants needed: 333
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Rapport Therapeutics Inc.Updated: Jun 16, 2026Locations: 3
Eligibility criteria

Age 18 - 75 [+5]

Known hypersensitivity or prior exposure to RAP-219. [+8]

Read more
Status: Recruiting

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Rapport Therapeutics Inc.Updated: Jan 23, 2026Locations: 7
Eligibility criteria

Completion of the associated parent study (RAP-219-FOS-201) treatment period wit... [+6]

Known of hypersensitivity to RAP-219 [+2]

Read more